RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsThe number of patients at later time points in the Alpine Immune Science povetacicept phase 1b clinical trial, now reported as a Phase 3 ready clinical candidate, is only six patients in the 80mg dose arm reaching week 36 and just one patient reaching week 48 in the trial.
On this limited Phase 1b clinical data in a small population of trial patients, Vertex acquired Alpine Immune Science in an all cash US$4.9 Billion deal, which demonstrates that Big Pharma is eager and willing to conduct multi-billion deals for early stage clinical development companies in an effort to fill their product portfolios and mitigate the patent cliff that has been discussed on this message board.